Screening tools for detecting problematic opioid use and potential application to community pharmacy practice: a review

References

• Passik SD, Kirsh KL, Casper D. Addiction-related assessment tools and pain management: instruments for screening, treatment planning, and monitoring compliance. Pain Med. 2008;9(Suppl 2):S145–S166. doi:10.1111/j.1526-4637.2008.00486.x
   Web of Science ®Google Scholar
• SAMHSA. Behavioral Health Trends in the United States: Results from the 2017 National Survey on Drug Use and Health. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2018.
   Google Scholar
• SAMHSA. Key Substance Use and Mental Health Indicators in the United States: Results from the 2017 National Survey on Drug Use and Health (HHS Publication No. SMA 18-5068, NSDUH Series H-53). Rockville, MD: Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality; 2018.
   Google Scholar
• Seth P, Scholl L, Rudd R, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016. MMWR Morb Mortal Wkly Rep. 2018;67:349–358.29596405
   PubMed Web of Science ®Google Scholar
• N K. The economic burden of opioid abuse: updated findings. J Manag Care Spec Pharm. 2017;23(4):427–445.28345440
   PubMedGoogle Scholar
• Amari E. Nonmedical prescription opioid use and mental health and pain comorbidities: a narrative review. Can J Psychiatry. 2011;56(8):495–502. doi:10.1177/07067437110560080821878161
   PubMed Web of Science ®Google Scholar
• Martins S. Pathways between nonmedical opioid use/dependence and psychiatric disorders: results from the National epidemiologic survey on alcohol and related conditions. Drug Alcohol Depend. 2009;103(1–2):16–24. doi:10.1016/j.drugalcdep.2009.01.01919414225
   PubMed Web of Science ®Google Scholar
• Novak S. Physical pain, common psychiatric and substance use disorders, and the non-medical use of prescription analgesics in the United States. Drug Alcohol Depend. 2009;100(1–2):63–70. doi:10.1016/j.drugalcdep.2008.09.01319010611
   PubMed Web of Science ®Google Scholar
• Schwartz AC, Bradley R, Penza KM, et al. Pain medication use among patients with posttraumatic stress disorder. Psychosomatics. 2006;47(2):136–142. doi:10.1176/appi.psy.47.2.13616508025
   PubMed Web of Science ®Google Scholar
• Patel RS, Elmaadawi A, Nasr S, Haskin J. Comorbid post-traumatic stress disorder and opioid dependence. Cureus. 2017;9(9):e1647.29142795
   PubMed Web of Science ®Google Scholar
• Bilevicius E, Sommer JL, Asmundson GJG, El-Gabalawy R. Posttraumatic stress disorder and chronic pain are associated with opioid use disorder: results from a 2012–2013 American nationally representative survey. Drug Alcohol Depend. 2018;188:119–125. doi:10.1016/j.drugalcdep.2018.04.00529775955
   PubMed Web of Science ®Google Scholar
• Becker W. Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates. Drug Alcohol Depend. 2008;94(1–3):38–47. doi:10.1016/j.drugalcdep.2007.09.01818063321
   PubMed Web of Science ®Google Scholar
• Wilson-Poe A, Moron J. The dynamic interaction between pain and opioid misuse. Br J Pharmacol. 2018;175:2770–2777. doi:10.1111/bph.1387328602044
   PubMed Web of Science ®Google Scholar
• Cochran G, Hruschak V, DeFosse B, Hohmeier KC. Prescription opioid abuse: pharmacists’ perspective and response. Integ Pharm Res Pract. 2016;5:65–73. doi:10.2147/IPRP.S99539
   PubMed Web of Science ®Google Scholar
• Wu L-T, Ghitza UE, Burns AL, Mannelli P. The opioid overdose epidemic: opportunities for pharmacists. Subst Abuse Rehabil. 2017;8:53–55. doi:10.2147/SAR.S14426828814912
   PubMed Web of Science ®Google Scholar
• Qato DM, Zenk S, Wilder J, Harrington R, Gasksin D, Alexander G. The availability of pharmacies in the United States: 2007–2015. PLoS One. 2017;12:8. doi:10.1371/journal.pone.0183172
   Web of Science ®Google Scholar
• CDC. Select Features of State Pharmacist Collaborative Practice Laws. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2013.
   Google Scholar
• Hoppe J, Howland MA, Nelson L. The role of pharmacies and pharmacists in managing controlled substance dispensing. Pain Med. 2014;15:1996–1998. doi:10.1111/pme.1253125138390
   PubMed Web of Science ®Google Scholar
• Toblin RL, Paulozzi LJ, Logan JE, Hall AJ, Kaplan JA. Mental illness and psychotropic drug use among prescription drug overdose deaths: a medical examiner chart review. J Clin Psychiatry. 2010;71(4):491–496. doi:10.4088/JCP.09m05567blu20409446
   PubMed Web of Science ®Google Scholar
• Ferries EA, Gilson AM, Aparasu RR, Chen H, Johnson ML, Fleming ML. The prevalence of and factors associated with receiving concurrent controlled substance prescriptions. Subst Use Misues. 2017;52(12):1639–1645.
   PubMed Web of Science ®Google Scholar
• Paulozzi LJ, Logan JE, Hall AJ, McKinstry E, Kaplan JA, Crosby AE. A comparison of drug overdose deaths involving methadone and other opioid analgesics in West Virginia. Addiction. 2009;104(9):1541–1548. doi:10.1111/add.2009.104.issue-919686524
   PubMed Web of Science ®Google Scholar
• Wilsey BL, Fishman SM, Gilson AM, et al. Profiling multiple provider prescribing of opioids, benzodiazepines, stimulants, and anorectics. Drug Alcohol Depend. 2010;112(1–2):99–106. doi:10.1016/j.drugalcdep.2010.05.00720566252
   PubMed Web of Science ®Google Scholar
• Sowa EM, Fellers JC, Raisinghani RS, et al. Prevalence of substance misuse in new patients in an outpatient psychiatry clinic using a prescription monitoring program. Prim Care Companion CNS Disord. 2014;16:1.
   Google Scholar
• Paulozzi LJ, Strickler GK, Kreiner PW, Koris CM. Controlled substance prescribing patterns–prescription behavior surveillance system, eight states, 2013. MMWR Surveill Summ. 2015;64(9):1–14. doi:10.15585/mmwr.ss6409a1
   PubMed Web of Science ®Google Scholar
• Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 2012;125(1–2):8–18. doi:10.1016/j.drugalcdep.2012.07.00422857878
   PubMed Web of Science ®Google Scholar
• Riffkin R. Americans rate nurses highest on honesty, ethical standards. 2014; Available from: http://www.webcitation.org/6hZbvKPDQ. Accessed 517, 2016.
   Google Scholar
• Cochran G, Field C, Lawson K, Erickson C. Pharmacists’ knowledge, attitudes and beliefs regarding screening and brief intervention for prescription opioid abuse: a survey of Utah and Texas pharmacists. J Pharm Health Serv Res. 2013;4(2):71–79. doi:10.1111/jphs.12013
   Google Scholar
• Balough MM, Nwankpa S, Unni EJ. Readiness of pharmacists based in Utah about pain management and opioid dispensing. Pharmacy (Basel). 2019;7(1):11. doi:10.3390/pharmacy7010011
   Google Scholar
• Jones T, Schmidt M, Moore T. Further validation of an opioid risk assessment tool: the brief risk questionnaire. Ann Psychiatry Ment Health. 2015;3:3.
   Google Scholar
• McCaffrey S. Development of a brief version of the Current Opioid Misuse Measure (COMM): the COMM-9. Pain Med. 2019;20:113–118. doi:10.1093/pm/pny20529237039
   PubMed Web of Science ®Google Scholar
• Raistrick D. Development of the Leeds Dependence Questionnaire (LDQ): a questionnaire to measure alcohol and opiate dependence in the context of a treatment evaluation package. Addiction. 1994;89:563–572.8044122
   PubMed Web of Science ®Google Scholar
• Wickersham J. Validation of a brief measure of opioid dependence: the Rapid Opioid Dependence Screen (RODS). J Correct Health Care. 2015;21(1):12–26. doi:10.1177/107834581455751325559628
   PubMed Web of Science ®Google Scholar
• Rawson RA, Maxwell J, Rutkowski B. OxyContin abuse: who are the users? Am J Psychiatry. 2007;1634–1636. doi:10.1176/appi.ajp.2007.0709139317974924
   PubMed Web of Science ®Google Scholar
• Webster L. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain Med. 2005;6(6):432–442. doi:10.1111/j.1526-4637.2005.00072.x16336480
   PubMed Web of Science ®Google Scholar
• Adams L, Gatchel R, Robinson R, et al. Development of a self-report screening instrument for assessing potential opioid medication misuse in chronic pain patients. J Pain Symptom Manage. 2004;27(5):440–459. doi:10.1016/j.jpainsymman.2003.10.00915120773
   PubMed Web of Science ®Google Scholar
• Knisely JS, Wunsch MJ, Cropsey KL, Campbell ED. Prescription opioid misuse index: a brief questionnaire to assess misuse. J Subst Abuse Treat. 2008;35(4):380–386. doi:10.1016/j.jsat.2008.02.00118657935
   PubMed Web of Science ®Google Scholar
• Butler S, Fernandez K, Benoit C, Budman S, Jamison R. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain. 2008;9(4):360–372. doi:10.1016/j.jpain.2007.11.01418203666
   PubMed Web of Science ®Google Scholar
• Gryczynski J. Validation of the TAPS-1: a four-item screening tool to identify unhealthy substance use in primary care. J Gen Intern Med. 2017;32(9):990–996. doi:10.1007/s11606-016-3934-528550609
   PubMed Web of Science ®Google Scholar
• Wunsch MJ, Cropsey KL, Campbell ED, Knisely JS. OxyContin use and misuse in three populations: substance abuse patients, pain patients, and criminal justice participants. J Opioid Manag. 2008;4(2):73–79. doi:10.5055/jom.2008.001118557163
   PubMedGoogle Scholar
• Cochran G, Lo-Ciganic W, Gellad W, et al. Prescription opioid quality measures applied among pennsylvania medicaid enrollees. J Manag Care Spec Pharm. 2018;24(9):875–885. doi:10.18553/jmcp.2018.24.3.19130156454
   PubMed Web of Science ®Google Scholar
• Compton WM, Denisco R. Prescription drug abuse In: Galanter M, Kleber HD, editors. The American Psychiatric Publishing Textbook of Substance Abuse Treatment. 4th ed. Arlington, VA US: American Psychiatric Publishing, Inc.; 2008:595–607.
   Google Scholar
• Cochran G, Bacci J, Ylioja T, et al. Prescription opioid use: patient characteristics and misuse in community pharmacy. J Am Pharm Assoc (2003). 2016;56:248–256. doi:10.1016/j.japh.2016.01.00827053277
   PubMed Web of Science ®Google Scholar
• McNeely J, Wu LT, Subramaniam G, et al. Performance of the Tobacco, Alcohol, Prescription Medication, and Other Substance Use (TAPS) tool for substance use screening in primary care patients. Ann Intern Med. 2016;165(10):690–699. doi:10.7326/M16-031727595276
   PubMed Web of Science ®Google Scholar
• Cochran G, Field C, Hruschak V, Seybert A, Gordon A, Tarter R. Community pharmacy-led intervention for opioid medication misuse (June, 2019). College on Problems of Drug Dependence, 81st Annual Meeting, San Antonio, TX.
   Google Scholar
• Shafer E, Bergeron N, Smith-Ray R, Robson C, O’Koren R. A nationwide pharmacy chain responds to the opioid epidemic. J Am Pharm Assoc (2003). 2017;57(2):S123–S129.28163028
   PubMed Web of Science ®Google Scholar
• Bao Y, Pan Y, Taylor A, et al. Prescription drug monitoring programs are associated with sustained reductions in opioid prescribing by physicians. Health Aff (Millwood). 2016;35(6):1045–1051. doi:10.1377/hlthaff.2015.167327269021
   PubMed Web of Science ®Google Scholar
• Dowell D, Zhang K, Noonan RK, Hockenberry JM. Mandatory provider review and pain clinic laws reduce the amounts of opioids prescribed and overdose death rates. Health Aff (Millwood). 2016;35(10):1876–1883. doi:10.1377/hlthaff.2016.044827702962
   PubMed Web of Science ®Google Scholar
• Ali MM, Dowd WN, Classen T, Mutter R, Novak SP. Prescription drug monitoring programs, nonmedical use of prescription drugs, and heroin use: evidence from the National survey of drug use and health. Addict Behav. 2017;69:65–77. doi:10.1016/j.addbeh.2017.01.01128152391
   PubMed Web of Science ®Google Scholar
• Kreiner PW, Strickler GK, Undurraga EA, Torres ME, Nikitin RV, Rogers A. Validation of prescriber risk indicators obtained from prescription drug monitoring program data. Drug Alcohol Depend. 2017;173(Suppl 1):S31–s38. doi:10.1016/j.drugalcdep.2016.11.02028363317
   PubMed Web of Science ®Google Scholar
• Young LD, Kreiner PW, Panas L. Unsolicited reporting to prescribers of opioid analgesics by a state prescription drug monitoring program: an observational study with matched comparison group. Pain Med. 2017;19(7):1396–1407.
   Web of Science ®Google Scholar
• Moyo P, Simoni-Wastila L, Griffin BA, et al. Impact of prescription drug monitoring programs (PDMPs) on opioid utilization among medicare beneficiaries in 10 US States. Addiction. 2017;112(10):1784–1796. doi:10.1111/add.1386028498498
   PubMed Web of Science ®Google Scholar
• Paulozzi LJ, Kilbourne EM, Desai HA. Prescription drug monitoring programs and death rates from drug overdose. Pain Med. 2011;12(5):747–754. doi:10.1111/j.1526-4637.2011.01062.x21332934
   PubMed Web of Science ®Google Scholar
• Patrick SW, Fry CE, Jones TF, Buntin MB. Implementation of prescription drug monitoring programs associated with reductions in opioid-related death rates. Health Aff (Millwood). 2016;35(7):1324–1332. doi:10.1377/hlthaff.2015.149627335101
   PubMed Web of Science ®Google Scholar
• Nam YH, Shea DG, Shi Y, Moran JR. State prescription drug monitoring programs and fatal drug overdoses. Am J Manag Care. 2017;23(5):297–303.28738683
   PubMed Web of Science ®Google Scholar
• Haegerich TM, Paulozzi LJ, Manns BJ, Jones CM. What we know, and don’t know, about the impact of state policy and systems-level interventions on prescription drug overdose. Drug Alcohol Depend. 2014;145:34–47. doi:10.1016/j.drugalcdep.2014.10.00125454406
   PubMed Web of Science ®Google Scholar
• Green T, Case P, Fiske H, et al. Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states. J Am Pharm Assoc (2003). 2017;57:S19–S27. doi:10.1016/j.japh.2017.01.01328214219
   PubMed Web of Science ®Google Scholar
• Mdege N, Lang J. Screening instruments for detecting illicit drug use/abuse that could be useful in general hospital wards: a systematic review. Addict Behav. 2011;36:1111–1119. doi:10.1016/j.addbeh.2011.01.00821821364
   PubMed Web of Science ®Google Scholar